(Benzoyl peroxide + tretinoin) is under clinical development by Ortho Dermatologics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Benzoyl peroxide + tretinoin)’s likelihood of approval (LoA) and phase transition for Acne Vulgaris took place on 12 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Benzoyl peroxide + tretinoin) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Benzoyl peroxide + tretinoin) overview

IDP-120(A fixed dose combination of benzoyl peroxide and tretinoin) is under development for the treatment of acne vulgaris. It is administered topically as a gel .Benzoyl peroxide is a powerful antimicrobial agent and tretinoin is a naturally occurring retinoic acid that acts by targeting the retinoic acid receptors (RARs).

Quick View (Benzoyl peroxide + tretinoin) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Benzoyl peroxide + tretinoin)
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.